We are live on ! Find out more

uniQure

QURE

Market cap $3.53B

50.95 USD

-0.10

0.2%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

50.75

-0.20

0.39%

1 day

-0.2%

5 days

6.15%

1 month

33.34%

3 months

102.58%

6 months

197.61%

Year to date

117.83%

1 year

222.67%

5 years

79.21%

10 years

500.12%

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Employees: 221

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 56.7%

Neutral 33.3%

Negative 10%

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Zacks Investment Research

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure Q2 Earnings Call Highlights

uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026.

uniQure Q2 Earnings Call Highlights

Zacks Investment Research

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130 and continued pipeline investment ~ ~ uniQure to host earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass.

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure to Announce Second Quarter 2026 Financial Results

~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~

uniQure to Announce Second Quarter 2026 Financial Results

Zacks Investment Research

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

Zacks Investment Research

Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?

QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.

Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?

Zacks Investment Research

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

See News Rankings

Price charts implemented using Lightweight Charts™